Successful Desensitization to Pembrolizumab in Patients with Severe Hypersensitivity Reactions, one of Them with Mastocytosis: Report of Three Cases and Review of The Literature
1. Case Report Pembrolizumab is a humanized IgG4 monoclonal antibody targeting the PD-1 receptor, approved for immunotherapy in advanced cancers (melanoma, non-small cell cancer, Hodgkin lymphoma, bladder cancer, etc.) [1].